Background: Cancer is not only a physiological disease but also a complex condition that profoundly affects an individual’s psychological well-being and social relationships. Misconceptions about cancer within the public, including its association with death and the tendency to attribute blame to patients as being “personally responsible,” contribute to the development of social stigma among cancer survivors. This stigma negatively impacts patients’ engagement in treatment and their quality of life, highlighting the need to assess societal attitudes based on survivors’ lived experiences. Aim: To examine the everyday lived experiences of cancer survivors, measure perceived social stigma, and identify psychological challenges as well as sources of support. Materials and Methods: A mixed-methods design was employed. In the quantitative component, the Cancer Stigma Scale (CASS) and the Attitudes Toward Cancer Questionnaire (ATCQ) were translated and their content validity was evaluated by an expert panel using the Content Validity Index (CVI), followed by pilot testing to confirm feasibility (FVI). In the qualitative component, focus group discussions were conducted with cancer survivors, and coping ability was assessed using psychological assessment tools. Result: A total of 207 participants (68% female; mean age 33.82±13.7 years) were included in the quantitative study. Participants experienced a moderate level of cancer-related stigma, with negative attitudes most strongly associated with perceptions of disease severity and individual responsibility. Qualitative findings revealed that physician communication and family support played a decisive role in psychological responses at the time of diagnosis disclosure. Excessive sympathy or social distancing increased psychological distress, whereas normal interpersonal interaction and realistic encouragement were identified as the most effective forms of support. Conclusion To improve psychosocial support for cancer survivors, it is essential to enhance healthcare professionals’ communication skills, promote accurate public understanding of cancer, and strengthen the sustainability of survivor support group activities.

Background Varicose veins, or chronic venous insufficiency, become visibly noticeable from the second stage when veins start appearing on the surface of the skin. Symptoms include severe itching, pain, swelling, and inflammation. Chronic venous insufficiency is a common condition in countries such as China, South Korea, Japan, Mongolia, and Kazakhstan. Diagnosis of varicose veins relies on blood flow studies, coagulation tests, contrast-enhanced magnetic resonance imaging (MRI), and Doppler ultrasound of the venous system. Patient B, a 43-year-old male, has experienced pain and swelling in the right lower limb vein for the past two years, especially when exposed to heat. Coagulation tests show PT and PT INR within normal range. Doppler ultrasound of the venous system revealed that the perforating vein is dilated to 0.45 cm and has valve insufficiency. In the deep veins, a width of 0.68 cm was measured, while superficial veins ranged between 0.46–0.59 cm. After receiving appropriate treatment from the Department of Fire Acupuncture, the patient’s symptoms have improved.

Clinical characteristics differences and risk factors of coronavirus disease and influenza in children 0-18 years Background: In worldwide, 176190 children infected with SARS-CoV-2 during April of 2020. According 01/09/2021, 46019 children had diagnosed with COVID-19 in Mongolia, were 19.5% of all cases. During COVID-19 infection, respiratory and digestive symptoms were commonly presented in children. Although the symptoms of coronavirus disease in children and adults are similar, in general, it was relatively mildly than adults, but from clinical observations reported that the infection occurs more severely in children and leads to death. During the coronavirus pandemic, it has been reported that children have Kawasaki syndrome, cardiac myopathy, coronary artery changes, and digestive system problems. Cardiac dysfunction in children may have recovered without sequelae, and further long-term follow-up studies are necessary. We aimed study clinical characteristics differences and risk factors of coronavirus disease and influenza in children 0-18 years. Materials and methods: The study was conducted Children hospital of NCMCH from October 01, 2021 to April 01, 2022, participated 594 inpatients with COVID-19 and influenza, and studied clinical characteristics, laboratory and functional diagnostic changes, treatment, and complications of the coronavirus disease and influenza. Results: The study included 450 children aged 0-18 years with confirmed COVID-19 infection and 144 children with influenza. In social-demographic indicators, the mean age of children is 4±4.8 years, and 58.6% are male. Children age group included 0-4 ages, 5-9 ages, 10-15 ages and over 15 ages (62.4%, 17.5%, 16.2%, and 3.7%), respectively. As for influenza, 39.7% were children aged 0-9. In 8 cases, they received the COVID-19 vaccine but became ill with COVID-19. As for the variants of COVID-19 infection, 231(41.8%) alpha, 219(48.0%) delta, and 144(24.2%) influenza according to the wave period and clinical differentiation. In severity of diseases, 2(0.4%) were mild, 312(69.3%) were moderate, 117(26.0%) were severe, and 17(3.8%) were critical severe. There is a statistically significant difference in the severity of the disease between COVID-19 and influenza. 1 death (0.4%) occurred in cases of COVID-19. The mean days of inpatients with COVID-19 was 12.4±5.5 and mean days of inpatients with influenza 8.6±3.64. When assess signs of children, fever, cough and food aversion were main signs among both group of alpha and delta varientin COVID-19. Specifically, 67.3% had fever, 63.3% cough, 16.4% runny nose, 8% chest pain, 10.2% headache, 15.5% fatigue, and 0.9% decreased sense of taste and smell. There is a statistically significant difference (p<0.000) in the symptoms of cough, chest pain, general toxication symptoms and decreased sense of taste and smell in the case of COVID-19 and influenza. During influenza, symptoms of chest tightness and respiratory distress were observed in 10 (7.4%) children during severe illness. 0.5% of all cases of COVID-19 with sinus arrhythmia, and atrioventricular block were detected 0.9% of all cases by electrocardiogram analysis. When studying the underlying medical conditions of children in relation to the complications of COVID-19 and influenza, children diagnosed with heart defects, malnutrition, weakness, anemia, cerebral palsy, and other chronic diseases have a greater impact on the severity of the disease of COVID-19 than those with influenza. In the study of the factors affecting the severity of the COVID-19 infection, the child's age and gender did not have an effect, while the presence of a heart defect in the child increased the risk of complications by 5 times (p<0.001). Conclusions: Among 0-4 aged children with COVID-19 are occurred more hospitalization, brightly presented symptoms in children with chronic diseases, are being more severe and hospitalization days are more than in children with influenza. Symptoms of fever, cough, and runny nose are more common in children during flu and influenza, while headache, abdominal pain, dehydration, and reduced sense of taste and smell are significantly more common in the case of COVID-19. On the other hand, symptoms of chest pain, weakness, and fatigue were found in the 2 groups. The comorbidities (congenital cardiac anomalies, malnutrition, weakness, anemia, cerebral palsy, and other chronic diseases) are being risk factors for the severity of coronavirus disease.

The result of endovascular surgical treatment of congenital heart disease Background: Over the last 10 years the advances in catheter based interventions for congenital heart disease(CHD) include new procedures, devices and almost 25% of all CHD are now can be treated by endovascular surgery. The purpose of this report was to evaluate the outcome and result of endovascular surgeries for congenital heart disease. Materials and methods: The study included all cases of endovascular surgeries at the National Center for Maternal and Child Health the period of 2014-2019. Results: Total 631 cases had intervention procedures and 377 (59.7%) cases had endovascular surgeries for CHD. 268 patients had patent ductus arteriosus device closure successfully while 57 had pulmonary artery valvuloplasty using balloons. Also 76 patients had device closure of atrial septal defect and 4 patients had device closure of ventricular septal defect using new multifunctional occluder. Another 20 patients had severe coarctation of aorta and had balloon dilatation and stenting as a life saving procedure. Conclusions: Endovascular surgery for CHD is a safe and effective alternative to open heart surgery.

Traditional medicine describes common flu as excessof blood and bile heat combined with microbes which results infectious heat. Deva-5is a decoction used which treats infectious heat. The aim of this study is to analyze components of Deva-5 decoction by traditional methods. Deva- 5 is composed of Gentianadecumbens L., Terminalia Chebula Retz., Polygonium bistorta L., Momordica cochinchinensis (Lour) and Chiazospermum erectum Bernh.It has a cool power and dispels infectious heat andkills microbes. The main component of the decoctionis Gentiana decumbens L. Ithas a sweat taste and clears heat, kills microbes, and cures typhus. Medical practitioners of Mongolia, Tibet, and Tuva use Gentiana decumbens L.as a substitution to deva (sngo-de-ba).It has a bitter taste and a cool power. It also has antimicrobial and heat clearing effects. All components of Deva-5 decoction have a cool power and the decoction is compounded by power.

Traditional medicine describes common flu as excess of blood and bile heat combined with microbes which results infectious heat. Deva-5 is a decoction used which treats infectious heat. The aim of this study is to analyze components of Deva-5 decoction by traditional methods. Deva-5 is composed of Gentiana decumbens L., Terminalia Chebula Retz., Polygonium bistorta L., Momordica cochinchinensis (Lour) and Chiazospermum erectum Bernh. It has a cool power and dispels infectious heat and kills microbes. The main component of the decoction is Gentiana decumbens L. It has a sweat taste and clears heat, kills microbes, and cures typhus. The effects of water extract of Deva-5 on pathogenic bacteria including Streptococcus pneumonia, Staphylococus aureus, and Escherichia coli were examined. Plates of bacteria treated with Deva-5 at 6 different concentrations (1 -30 %) were incubated at 37°C for 24 h and then the diameter of the circle of bacterial growth was measured. Amoxicillin, nistatin, flukanosol, and ciprofloxacin were used as comparison. Acute and chronic toxicities of Deva-5 were determined in mice. Deva-5 was given orally to mice at doses of 200 mg/kg and 500 mg/kg for 28 days. In addition, therapeutic dose of Deva-5 was also determined in mice. Deva-5 inhibited growths of Streptococcus pneumonia and Staphylococus aureus at concentrations of 5 %, 10 %, 20 %, and 30 %. Deva-5 more effectively inhibited growth of Streptococcus pneumonia than that of Staphylococus aureus. Growth of Escherichia coli was not inhibited by Deva-5 treatment. The median lethal dose of (LD50) of Deva-5 was 6.89 g/kg. There were no difference between the control and Deva-5-treated groups in movements, hair color, food consumption, and the number of offspring of mice. No histopathological changes were observed in solid organs of animals treated with Deva-5. Therapeutic doses of Deva-5 were found to be 50-150 mg/kg. These results suggest that Deva-5 has antibacterial effects in vitro and it is safe in mice.